

LABORATORY REPORT



Patient Name : [REDACTED]

DOB/Age/Gender : 23 Y/Male

Patient ID / UHID : [REDACTED]

Referred By : Dr.

Sample Type : Whole blood EDTA

Barcode No : HY214335

Bill Date : Mar 05, 2024, 05:16 PM

Sample Collected : Mar 06, 2024, 10:53 AM

Sample Received : Mar 06, 2024, 01:14 PM

Report Date : Mar 06, 2024, 03:09 PM

Report Status : Final Report

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

HEMATOLOGY REPORT
Premium Package 2 : MALE (127 Tests)
Complete Blood Count (CBC)

RBC Parameters

Hemoglobin	15.6	g/dL	13.0 - 17.0
Method : colorimetric			
RBC Count	5	10 ⁶ /μl	4.5 - 5.5
Method : Electrical impedance			
PCV	45.2	%	40 - 50
Method : Calculated			
MCV	89.5	fl	83 - 101
Method : Calculated			
MCH	30.8	pg	27 - 32
Method : Calculated			
MCHC	34.4	g/dL	31.5 - 34.5
Method : Calculated			
RDW (CV)	12.4	%	11.6 - 14.0
Method : Calculated			
RDW-SD	41.2	fl	35.1 - 43.9
Method : Calculated			

WBC Parameters

TLC	8.3	10 ³ /μl	4 - 10
Method : Electrical impedance and microscopy			

Differential Leucocyte Count

Neutrophils	54	%	40-80
Lymphocytes	31	%	20-40
Monocytes	10	%	2-10
Eosinophils	5	%	1-6
Basophils	0	%	<2


Absolute Leukocyte Counts

Method : Calculated			
Neutrophils.	4.48	10 ³ /μl	2 - 7
Lymphocytes.	2.57	10 ³ /μl	1 - 3
Monocytes.	0.83	10 ³ /μl	0.2 - 1.0
Eosinophils.	0.42	10 ³ /μl	0.02 - 0.5
Basophils.	0	10 ³ /μl	0.02 - 0.5

Platelet Parameters

Platelet Count	250	10 ³ /μl	150 - 410
Method : Electrical impedance and microscopy			
Mean Platelet Volume (MPV)	9.8	fL	9.3 - 12.1

[Handwritten Signature]



LABORATORY REPORT




Patient Name :
DOB/Age/Gender : 23 Y/Male
Patient ID / UHID :
Referred By : Dr.
Sample Type : Whole blood EDTA
Barcode No : HY214335

Bill Date : Mar 05, 2024, 05:16 PM
Sample Collected : Mar 06, 2024, 10:53 AM
Sample Received : Mar 06, 2024, 01:14 PM
Report Date : Mar 06, 2024, 03:09 PM
Report Status : Final Report

Test Description	Value(s)	Unit(s)	Reference Range
Method : Calculated			
PCT	0.2	%	0.17 - 0.32
Method : Calculated			
PDW	16.2	fL	8.3 - 25.0
Method : Calculated			
P-LCR	31.5	%	18 - 50
Method : Calculated			
P-LCC	79	%	44 - 140
Method : Calculated			
Mentzer Index	17.9	%	-
Method : Calculated			

Interpretation:
CBC provides information about red cells, white cells and platelets. Results are useful in the diagnosis of anemia, infections, leukemias, clotting disorders and many other medical conditions.

[Handwritten Signature]



LABORATORY REPORT



Patient Name : [REDACTED]

DOB/Age/Gender : 23 Y/Male

Patient ID / UHID : [REDACTED]

Referred By : Dr.

Sample Type : FLUORIDE F

Barcode No : ZB803486

Bill Date : Mar 05, 2024, 05:16 PM

Sample Collected : Mar 06, 2024, 10:53 AM

Sample Received : Mar 06, 2024, 01:14 PM

Report Date : Mar 06, 2024, 02:53 PM

Report Status : Final Report

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

BIOCHEMISTRY REPORT
Premium Package 2 : MALE (127 Tests)
Glucose Fasting (BSF)

Glucose Fasting

82

mg/dL

70 - 100

Method : Hexokinase

Interpretation:

Status	Fasting plasma glucose in mg/dL
Normal	<100
Impaired fasting glucose	100 - 125
Diabetes	=>126


Reference : American Diabetes Association

Comment :

Blood glucose determinations in commonly used as an aid in the diagnosis and treatment of diabetes. Elevated glucose levels (hyperglycemia) may also occur with pancreatic neoplasm, hyperthyroidism, and adrenal cortical hyper function as well as other disorders. Decreased glucose levels (hypoglycemia) may result from excessive insulin therapy insulinoma, or various liver diseases.

Note

- 1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL or a random / 2 hour plasma glucose value of > or = 200 mg/dL with symptoms of diabetes mellitus.
- 2.Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis.



LABORATORY REPORT



Patient Name

:

DOB/Age/Gender

:

23 Y/Male

Patient ID / UHID

:

Referred By

:

Dr.

Sample Type

:

Serum

Barcode No

:

ZB803485

Bill Date

:

Mar 05, 2024, 05:16 PM

Sample Collected

:

Mar 06, 2024, 10:53 AM

Sample Received

:

Mar 06, 2024, 01:14 PM

Report Date

:

Mar 06, 2024, 02:53 PM

Report Status

:

Final Report

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

BIOCHEMISTRY REPORT
Premium Package 2 : MALE (127 Tests)

Lipid Profile

Total Cholesterol	181	mg/dL	<200
Method : Enzymatic - Cholesterol Oxidase			
Triglycerides	123	mg/dL	<150
Method : Glycerol Phosphate Oxidase			
HDL Cholesterol	47	mg/dL	>40
Method : Accelerator Selective Detergent			
Non HDL Cholesterol	134	mg/dL	<130
Method : Calculated			
LDL Cholesterol	109.4	mg/dL	<100
Method : Calculated			
V.L.D.L Cholesterol	24.6	mg/dL	< 30
Method : Calculated			
Chol/HDL Ratio	3.85	Ratio	3.5 - 5.0
Method : Calculated			
HDL/ LDL Ratio	0.43	Ratio	0.5 - 3.0
Method : Calculated			
LDL/HDL Ratio	2.33	Ratio	-
Method : Calculated			

Interpretation:
Lipid level assessments must be made following 9 to 12 hours of fasting, otherwise assay results might lead to erroneous interpretation. NCEP recommends of 3 different samples to be drawn at intervals of 1 week for harmonizing biological variables that might be encountered in single assays.


National Lipid Association Recommendations (NLA-2014)	Total Cholesterol (mg/dL)	Triglyceride (mg/dL)	LDL Cholesterol (mg/dL)	Non HDL Cholesterol (mg/dL)
Optimal	<200	<150	<100	<130
Above Optimal			100-129	130 - 159
Borderline High	200-239	150-199	130-159	160 - 189
High	>=240	200-499	160-189	190 - 219
Very High	-	>=500	>=190	>=220

HDL Cholesterol	
Low	High
<40	>=60


Risk Stratification for ASCVD (Atherosclerotic Cardiovascular Disease) by Lipid Association of India.

Risk Category	A. CAD with > 1 feature of high risk group
Extreme risk group	B. CAD with >1 feature of very high risk group of recurrent ACS (within 1 year) despite LDL-C <or = 50 mg/dl or poly vascular disease

[Handwritten Signature]



LABORATORY REPORT



Patient Name :

DOB/Age/Gender : 23 Y/Male

Patient ID / UHID :

Referred By : Dr.

Sample Type : Serum

Barcode No : ZB803485

Bill Date : Mar 05, 2024, 05:16 PM

Sample Collected : Mar 06, 2024, 10:53 AM

Sample Received : Mar 06, 2024, 01:14 PM

Report Date : Mar 06, 2024, 02:53 PM

Report Status : Final Report


Test Description	Value(s)	Unit(s)	Reference Range
Very High Risk	1.Established ASCVD 2.Diabetes with 2 major risk factors of evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia		
High Risk	1. Three major ASCVD risk factors 2. Diabetes with 1 major risk factor or no evidence of end organ damage 3. CHD stage 3B or 4. 4 LDL >190 mg/dl 5. Extreme of a single risk factor 6. Coronary Artery Calcium - CAC > 300 AU 7. Lipoprotein a >= 50 mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age >=45 years in Males & >= 55 years in Females	3. Current Cigarette smoking or tobacco use		
2. Family history of premature ASCVD	4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by Lipid Association of India in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal <OR = 30)	<80 (Optional goal <OR = 60)	>OR = 50	>OR = 80
Extreme Risk Group Category B	>OR = 30	>OR = 60	> 30	> 60
Very High Risk	<50	<80	>OR = 50	>OR = 80
High Risk	<70	<100	>OR = 70	>OR = 100
Moderate Risk	<100	<130	>OR = 100	>OR = 130
Low Risk	<100	<130	>OR = 130*	>OR = 160

* After an adequate non-pharmacological intervention for at least 3 months.

References : Management of Dyslipidaemia for the Prevention of Stroke : Clinical practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology,2022,20,134-155.



LABORATORY REPORT



Patient Name : [REDACTED]

DOB/Age/Gender : 23 Y/Male

Patient ID / UHID : [REDACTED]

Referred By : Dr.

Sample Type : Spot Urine

Barcode No : YA351103

Bill Date : Mar 05, 2024, 05:16 PM

Sample Collected : Mar 06, 2024, 10:53 AM

Sample Received : Mar 06, 2024, 01:14 PM

Report Date : Mar 06, 2024, 03:09 PM

Report Status : Final Report

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

CLINICAL PATHOLOGY REPORT
Premium Package 2 : MALE (127 Tests)
Urine Routine and Microscopic Examination

Physical Examination


Volume	20	ml	-
Colour	Pale yellow	-	Pale yellow
Transparency	Clear	-	Clear
Deposit	Absent	-	Absent

Chemical Examination

Reaction (pH) Method : Double Indicator	6.5	-	4.5 - 8.0
Specific Gravity Method : Ion Exchange	1.025	-	1.010 - 1.030
Urine Glucose (sugar) Method : Oxidase / Peroxidase	Negative	-	Negative
Urine Protein (Albumin) Method : Acid / Base Colour Excahnge	Negative	-	Negative
Urine Ketones (Acetone) Method : Legals Test	Negative	-	Negative
Blood Method : Peroxidase Hemoglobin	Negative	-	Negative
Leucocyte esterase Method : Enzymatic Reaction	Negative	-	Negative
Bilirubin Urine Method : Coupling Reaction	Negative	-	Negative
Nitrite Method : Griess Test	Negative	-	Negative
Urobilinogen Method : Ehrlichs Test	Normal	-	Normal

Microscopic Examination

Pus Cells (WBCs)	1-2	/hpf	0 - 5
Epithelial Cells	1-2	/hpf	0 - 4
Red blood Cells	Absent	/hpf	Absent
Crystals	Absent	-	Absent
Cast	Absent	-	Absent
Yeast Cells	Absent	-	Absent
Amorphous deposits	Absent	-	Absent
Bacteria	Absent	-	Absent
Protozoa	Absent	-	Absent



Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.